SLE
-
New Study Finds Cardiovascular Risk Control May Slow Atherosclerosis Progression in People with Systemic Lupus Erythematosus
.
Posted on June 4, 2026 A new study found that controlling traditional cardiovascular disease (CVD) risk factors, including blood pressure, cholesterol and smoking, may significantly reduce the progression of atherosclerosis in people with systemic lupus…
-
Phase 2 JASMINE Study Shows Nipocalimab Reduces Disease Activity in Adults with Systemic Lupus Erythematosus
.
Posted on June 3, 2026 Pharmaceutical company Johnson & Johnson announced new late-breaking results from its Phase 2 JASMINE study showing that investigational therapy nipocalimab significantly reduced disease activity in adults living with…
-
New Study Suggests Breath Testing Could Help Monitor Lupus Disease Activity and Fatigue
.
Posted on June 1, 2026 In a study published in the Annals of the Rheumatic Diseases researchers found that compounds detected in exhaled breath may offer a promising, noninvasive way to better…
-
SAPHNELO approved in the US for subcutaneous self-administration for treatment of systemic lupus erythematosus (SLE)
.
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active autoantibody-positive systemic lupus erythematosus (SLE). The 120 mg dose of the therapy…